TREATMENT
FOLFOXIRI Plus Panitumumab as First-Line Therapy for Left-Sided RAS Wild-Type Metastatic CRCA multicenter trial tested modified FOLFOXIRI combined with panitumumab every two weeks in patients with left-sided, RAS wild-type metastatic colorectal cancer. (The Oncologist)